[News] Research in Brief | ClinicLens

Daraxonrasib—an oral RAS(ON) multiselective inhibitor—significantly improves survival compared with standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, according to the phase 3 RASolute 302 trial. Eileen M O’Reilly and colleagues

Medical Literature · Updated 2026-08-03

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.